When Serena Williams told NBC’s “TODAY” show, “I just couldn’t get my weight to where I needed to be at a healthy place and ...

A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy.

Eli Lilly's GLP-1 pill, orforglipron, shows promising trial results for weight loss and type 2 diabetes. Global regulatory approval is planned for 2025.

In new Phase III trial data released Tuesday, people taking orforglipron lost substantially more weight than people taking a ...

The 36-mg dose brought the greatest weight loss, 10.5%, while the 12-mg dose group shed 7.8% of their body weight on average.

Novo Nordisk NVO suffered a major setback in July after slashing its 2025 sales and profit outlook, triggering a decline in ...

GLP-1 medications have been known to come with a raft of side effects, including weight loss and drastic changes to users' ...

Lilly said it’s moving ‘with urgency toward global regulatory submissions to potentially meet the needs of patients who are ...

NEW YORK - August 26, 2025 ( NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S (NYSE: NVO) of a class action securities lawsuit.

With around 73 percent of Americans enjoying their daily coffee fix, it’s natural to wonder how your morning cup might ...

You can’t scroll through social media or turn on the news without hearing about Ozempic. It’s the drug on everyone’s lips. In ...